Clinical trial
A Clinical Study to Evaluate the Effect of Pyronaridine on the Pharmacokinetics of MK-7602 in Healthy Participants
NCT07919028 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Clinical Study to Evaluate the Effect of Pyronaridine on the Pharmacokinetics of MK-7602 in Healthy Participants
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- January 4, 2027
- Completion date
- April 5, 2027
- Enrollment
- 24 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
healthy
Arms
As registered; 2 arms.
-
Period 1: MK-7602
Participants will receive an oral dose of MK-7602 once daily on Days 1, 2, and 3 of Period 1.
-
Period 2: MK-7602 + Pyronaridine
Participants will receive oral doses of MK-7602 and pyronaridine once daily on Days 1, 2, and 3 of Period 2.
Primary endpoints
Registered primary outcome measures; 4 primary.
-
Area Under the Curve From Time 0 to the Next Dosing Interval (AUC0-tau) of MK-7602
Blood samples will be collected to determine the AUC0-tau of MK-7602 with and without pyronaridine.
-
Maximum Plasma Concentration (Cmax) of MK-7602
Blood samples will be collected to determine the Cmax of MK-7602 with and without pyronaridine.
-
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. The number of participants who experience an AE will be reported.
-
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. The number of participants who discontinue study intervention due to an AE will be reported.
Lead sponsor's other trials
Merck Sharp & Dohme LLC, most recent start first.
+2,160 more trials